BR112016019534A2 - métodos de tratar o crescimento de um tumor e de suscitar uma resposta imune aprimorada contra o crescimento de tumor - Google Patents

métodos de tratar o crescimento de um tumor e de suscitar uma resposta imune aprimorada contra o crescimento de tumor

Info

Publication number
BR112016019534A2
BR112016019534A2 BR112016019534A BR112016019534A BR112016019534A2 BR 112016019534 A2 BR112016019534 A2 BR 112016019534A2 BR 112016019534 A BR112016019534 A BR 112016019534A BR 112016019534 A BR112016019534 A BR 112016019534A BR 112016019534 A2 BR112016019534 A2 BR 112016019534A2
Authority
BR
Brazil
Prior art keywords
tumor growth
methods
immune response
response against
eliciting
Prior art date
Application number
BR112016019534A
Other languages
English (en)
Portuguese (pt)
Inventor
Wallecha Anu
Seavey Matthew
MASON Nicola
C Maciag Paulo
Shahabi Vafa
Paterson Yvonne
Original Assignee
Advaxis Inc
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/189,008 external-priority patent/US20150366955A9/en
Priority claimed from US14/268,436 external-priority patent/US20140234370A1/en
Application filed by Advaxis Inc, Univ Pennsylvania filed Critical Advaxis Inc
Publication of BR112016019534A2 publication Critical patent/BR112016019534A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112016019534A 2014-02-25 2015-02-25 métodos de tratar o crescimento de um tumor e de suscitar uma resposta imune aprimorada contra o crescimento de tumor BR112016019534A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14/189,008 US20150366955A9 (en) 2009-11-11 2014-02-25 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US14/268,436 US20140234370A1 (en) 2009-11-11 2014-05-02 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US201462076411P 2014-11-06 2014-11-06
PCT/US2015/017559 WO2015130810A2 (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors

Publications (1)

Publication Number Publication Date
BR112016019534A2 true BR112016019534A2 (pt) 2017-10-24

Family

ID=54009773

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016019534A BR112016019534A2 (pt) 2014-02-25 2015-02-25 métodos de tratar o crescimento de um tumor e de suscitar uma resposta imune aprimorada contra o crescimento de tumor

Country Status (12)

Country Link
EP (1) EP3110942A4 (https=)
JP (1) JP2017507943A (https=)
KR (2) KR20240038103A (https=)
CN (1) CN106661538A (https=)
AU (1) AU2015223136A1 (https=)
BR (1) BR112016019534A2 (https=)
CA (1) CA2940646A1 (https=)
IL (1) IL247436A0 (https=)
MX (1) MX2016011114A (https=)
RU (1) RU2016137834A (https=)
SG (1) SG11201607036XA (https=)
WO (1) WO2015130810A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
WO2013138337A1 (en) 2012-03-12 2013-09-19 Advaxis Suppressor cell function inhibition following listeria vaccine treatment
JP2017511796A (ja) 2014-02-18 2017-04-27 アドバクシス， インコーポレイテッド 多標的免疫療法を目的とするバイオマーカー
AU2015227163A1 (en) * 2014-03-05 2016-10-20 Advaxis, Inc. Methods and compositions for increasing a T-effector cell to regulatory T cell ratio
EP3134510B1 (en) 2014-04-24 2023-11-01 Advaxis, Inc. Recombinant listeria vaccine strains and methods of producing the same
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
ES2970865T3 (es) 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
CA3035591A1 (en) 2016-11-30 2018-06-07 Advaxis, Inc. Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
AU2018336988B2 (en) 2017-09-19 2023-06-22 Advaxis, Inc. Compositions and methods for lyophilization of bacteria or Listeria strains
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855320B2 (en) * 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US9017660B2 (en) * 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors

Also Published As

Publication number Publication date
WO2015130810A2 (en) 2015-09-03
IL247436A0 (en) 2016-11-30
MX2016011114A (es) 2017-02-20
EP3110942A4 (en) 2017-08-30
KR20160122829A (ko) 2016-10-24
NZ723750A (en) 2024-02-23
CA2940646A1 (en) 2015-09-03
EP3110942A2 (en) 2017-01-04
AU2015223136A1 (en) 2016-09-22
KR20240038103A (ko) 2024-03-22
RU2016137834A (ru) 2018-03-29
CN106661538A (zh) 2017-05-10
SG11201607036XA (en) 2016-09-29
WO2015130810A3 (en) 2016-01-28
JP2017507943A (ja) 2017-03-23

Similar Documents

Publication Publication Date Title
BR112016019534A2 (pt) métodos de tratar o crescimento de um tumor e de suscitar uma resposta imune aprimorada contra o crescimento de tumor
CY1122602T1 (el) Αντιμετωπιση των nafld και nash
IL268704B (en) Formulations of human anti-rankl antibodies, and methods of using the same
IL263382A (en) Compositions and methods for tumor vaccination and immunotherapy involving her2/neu
SV2018005659A (es) Anticuerpos agonistas que se unen especificamente a cd40 humanos y metodos de uso
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
IL252159A0 (en) Methods and formulations for the treatment of diseases of the blood vessels of the eye
MX389560B (es) Enfoque de inmunoterapias de combinación para el tratamiento del cancer.
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
BR112016026378A2 (pt) formulações e métodos para tratamento com queratina
MX2021006734A (es) Metodo para tratar el cancer.
CL2016001871A1 (es) Anticuerpos humanos para pd-1
BR112017008959A2 (pt) método para tratamento de uma doença.
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2016009555A (es) Proteinas de union y metodos para utilizarlas.
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
MY176855A (en) Anti-jagged1 antibodies and methods of use
BR112016028910A2 (pt) sistema e método para ancoragem de válvula cardíaca
BR112017019025A2 (pt) aplicadores de implante e métodos para administrar implantes.
MX2017007595A (es) Inmunoterapia para enfermedad angiogenica.
MX2017005975A (es) Anticuerpos anti factor de crecimiento derivado de plaquetas b (pdgf-b) y metodos de uso.
UY36286A (es) Tratamientos médicos basados en anamorelina
CO2018008249A2 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]